hypoglycemia and glp-1 Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature Which of the following GLP-1
Description
Hathaway JT, Shah MP, Hathaway DB, Zekavat SM, Krasniqi D, Gittinger JW Jr, Cestari D, Mallery R, Abbasi B, Bouffard M, Chwalisz BK, Estrela T, Rizzo JF 3rd
GLP-1s are known to reduce both fat and muscle mass and discontinuation typically results in weight regainprimarily as fat massresulting in a less healthy body composition compared to treatment initiation
Blood sugar regulation changes on GLP-1 therapy as well
obtained from Boehringer Ingelheim, Ingelheim am Rhein, Germany)
10.1038/nmeth.4067 34 HussainA
Baisley and Baldo, 2014
